drugset / Trial / NCT04731233
Efficacy of PRGF Supplementation After TMJ Arthrocentesis in Patients With TMJ Osteoarthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
Temporomandibular joint (TMJ) osteoarthritis (OA) affects articulating tissues secondary to inflammation resulting in intracapsular pain. This prospective, double-blind randomized clinical trial will evaluate the relative efficacy of TMJ arthrocentesis with a supplementation of platelet-rich growth factors (PRGF) compared to TMJ arthrocentesis with a steroid supplementation (a known effective therapy) for patients with TMJ OA.
Timeline
- Start
- 2021-03-30
- Primary completion
- 2024-02-21
- Completion
- 2024-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plasma Rich in Growth Factor (PRGF) Supplementation | Protein / enzyme biologic | 2 ml | Other |
| Comparator | Triamcinolone Acetonide | Other / unclassified | 40 mg | Other |
| Comparator | Bupivacaine | Other / unclassified | 5 mg | Other |